The partners will develop vaccine candidates based on Themis’ measles virus vector-based platform. The vaccines are designed to deliver multiple selected antigens directly to macrophages and dendritic cells, thus triggering a specific immune response to the selected antigens . . .
- Cancer
- Drug Discovery
- GEN Edge
- Therapeutics
- Immuno-oncology
- Immunotherapies
- Industry News
- Translational Medicine
- Infectious Diseases
- Merck & Co
- News
- Vaccine Development
- Vaccines
Merck & Co. Partners with Themis on Measles Virus Vector-Based Vaccines
[Illustrator: Alissa Eckert / U.S. Centers for Disease Control and Prevention]